Hookipa Pharma Inc (NASDAQ:HOOK) Sees Large Growth in Short Interest

Hookipa Pharma Inc (NASDAQ:HOOK) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 39,500 shares, a growth of 9.1% from the October 31st total of 36,200 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 42,700 shares, the short-interest ratio is currently 0.9 days.

Hookipa Pharma Price Performance

HOOK stock opened at $2.58 on Tuesday. The company’s fifty day moving average price is $3.57 and its 200-day moving average price is $5.24. Hookipa Pharma has a one year low of $2.08 and a one year high of $11.30.

Hedge Funds Weigh In On Hookipa Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Hookipa Pharma during the first quarter valued at $31,000. Renaissance Technologies LLC boosted its holdings in Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after acquiring an additional 83,800 shares during the period. Ikarian Capital LLC bought a new position in Hookipa Pharma in the 3rd quarter valued at $228,000. Finally, Acadian Asset Management LLC boosted its position in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the period. 63.88% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on HOOK. Royal Bank of Canada dropped their target price on shares of Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating for the company in a report on Friday, November 15th. JMP Securities lowered their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 21st.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.